Coronavirus | Remdesivir production expected to start in Maharashtra’s Wardha from 28th April: Nitin Gadkari

Genetek LifeSciences to produce 30,000 vials of remdesivir injections per day, says the Union Minister

April 27, 2021 05:07 pm | Updated 05:07 pm IST - Nagpur

People stand in queues to get their COVID-19 coronavirus vaccine at a vaccination centre in Mumbai on April 26, 2021.

People stand in queues to get their COVID-19 coronavirus vaccine at a vaccination centre in Mumbai on April 26, 2021.

Union minister Nitin Gadkari on Tuesday said Genetek LifeSciences will start production of remdesivir injections, used in the treatment of COVID-19, in Wardha (Maharashtra) from Wednesday.

While speaking to reporters during the inauguration of a COVID-care centre in Nagpur, Mr. Gadkari said the company will produce 30,000 vials per day.

Remdesivir is approved in India for restricted emergency use for the treatment of suspected or laboratory confirmed COVID-19 in adults and children hospitalised with severe disease.

Genetek LifeSciences, based in Wardha, has received loan licence to manufacture remdesivir injections.

A team from Hyderabad has reached Wardha and the trials are underway and the production is expected to start from Wednesday, the minister said.

The remdesivir injections will be distributed in Nagpur and other districts of Vidarbha.

Similarly, it will be distributed in parts of Maharashtra as per the requirement and it will address the shortage of remdesivir injection.

Mr. Gadkari also talked about steps taken to streamline oxygen supply in Nagpur and also expressed confidence that the recovery situation will improve more in coming few days.

Mr.Gadkari was accompanied with BJP leader Devendra Fadnavis during the visit.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.